NEJM July 2026 Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma

This clinical study investigated whether extending lenalidomide treatment indefinitely provides better outcomes for multiple myeloma patients than stopping after a set two-year period. Researchers found that indefinite-duration therapy did not improve overall survival compared to the fixed-duration approach, with both groups showing nearly identical results after seven years. Furthermore, patients who continued treatment indefinitely experienced a higher incidence of adverse medical events and a slight increase in secondary cancers. Ultimately, the trial suggests that prolonged maintenance offers no significant survival advantage for this specific patient population and may lead to unnecessary physical complications.